Advertisement
Australia markets close in 30 minutes

  • ALL ORDS

    7,835.20
    -102.30 (-1.29%)
     

  • ASX 200

    7,574.20
    -108.80 (-1.42%)
     

  • AUD/USD

    0.6536
    +0.0013 (+0.20%)
     

  • OIL

    84.03
    +0.46 (+0.55%)
     

  • GOLD

    2,347.90
    +5.40 (+0.23%)
     

  • Bitcoin AUD

    98,421.11
    +145.19 (+0.15%)
     

  • CMC Crypto 200

    1,387.47
    +4.90 (+0.35%)
     

  • AUD/EUR

    0.6091
    +0.0018 (+0.30%)
     

  • AUD/NZD

    1.0964
    +0.0006 (+0.06%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,694.66
    +410.12 (+2.37%)
     

  • NIKKEI 225

    38,043.14
    +414.66 (+1.10%)
     

Pfizer says acquiring Medivation for $14 bn

AFP
Pfizer's net profit was $1.3 billion, down 38 percent from the year-ago period, while revenues were $13.0 billion, up eight percent

Pfizer will purchase biotech firm Medivation, which specializes in cancer treatments, for some $14 billion, the US pharma giant said in a statement on Monday.

Pfizer's offer for the San Francisco-based Medivation goes far beyond the company's market value of $11.1 billion.

The boards of directors of both companies have unanimously approved the merger, the statement said.

"The proposed acquisition of Medivation is expected to immediately accelerate revenue growth and drive overall earnings growth potential for Pfizer," said Ian Read, Pfizer chairman and chief executive officer.